MX2024001972A - Métodos y composiciones para tratar condiciones de hígado fibrótico, usando composiciones de udenafil - Google Patents

Métodos y composiciones para tratar condiciones de hígado fibrótico, usando composiciones de udenafil

Info

Publication number
MX2024001972A
MX2024001972A MX2024001972A MX2024001972A MX2024001972A MX 2024001972 A MX2024001972 A MX 2024001972A MX 2024001972 A MX2024001972 A MX 2024001972A MX 2024001972 A MX2024001972 A MX 2024001972A MX 2024001972 A MX2024001972 A MX 2024001972A
Authority
MX
Mexico
Prior art keywords
compositions
fibrotic
liver
udenafil
fibrotic liver
Prior art date
Application number
MX2024001972A
Other languages
English (en)
Spanish (es)
Inventor
David J Goldberg
Mark W Russell
Kurt R Schumacher
James L Yeager
Original Assignee
Mezzion Pharma Co Ltd
David J Goldberg
Mark W Russell
Kurt R Schumacher
James L Yeager
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd, David J Goldberg, Mark W Russell, Kurt R Schumacher, James L Yeager filed Critical Mezzion Pharma Co Ltd
Publication of MX2024001972A publication Critical patent/MX2024001972A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2024001972A 2021-08-13 2024-02-13 Métodos y composiciones para tratar condiciones de hígado fibrótico, usando composiciones de udenafil MX2024001972A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163233133P 2021-08-13 2021-08-13
PCT/US2022/040227 WO2023018972A1 (en) 2021-08-13 2022-08-12 Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Publications (1)

Publication Number Publication Date
MX2024001972A true MX2024001972A (es) 2024-11-08

Family

ID=83355014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001972A MX2024001972A (es) 2021-08-13 2024-02-13 Métodos y composiciones para tratar condiciones de hígado fibrótico, usando composiciones de udenafil

Country Status (7)

Country Link
US (2) US20230218622A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384176A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532957A (cg-RX-API-DMAC7.html)
AU (1) AU2022325803A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229274A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001972A (cg-RX-API-DMAC7.html)
WO (1) WO2023018972A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396708B2 (en) * 2024-01-08 2025-08-26 Echosens Sa Method for determining an index for assessing a cardiac function of a subject
EP4582017A1 (en) * 2024-01-08 2025-07-09 Echosens Method for determining an index for assessing a cardiac function of a subject

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
EP1888074B1 (en) * 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
MX390977B (es) 2014-08-12 2025-03-21 Mezzion Pharma Co Ltd Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo

Also Published As

Publication number Publication date
EP4384176A1 (en) 2024-06-19
CA3229274A1 (en) 2023-02-16
JP2024532957A (ja) 2024-09-10
WO2023018972A1 (en) 2023-02-16
US20230218622A1 (en) 2023-07-13
US20250186448A1 (en) 2025-06-12
AU2022325803A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
Wilhelmi et al. Bipedicle paraspinous muscle flaps for spinal wound closure: an anatomic and clinical study
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2025000319A (es) Inhibidores de integrina y usos de los mismos en combinacion con otros agentes
Petzold et al. Hyperbaric oxygen therapy in deep sternal wound infection after heart transplantation
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
JP2022550734A5 (cg-RX-API-DMAC7.html)
MX2025003110A (es) Metodo para tratar vih con cabotegravir y rilpivirina en pacientes pediatricos
ZA202311241B (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
WO2006104086A1 (ja) 血栓症治療剤
WO2022171732A9 (en) Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
RU2252754C2 (ru) Применение карипорида для уменьшения нежелательных воздействий макролидных антибиотиков при ишемии и реперфузии сердца
Olding et al. Emergency free flap reconstruction of a facial gunshot wound
HUP0301451A2 (hu) CGMP PDE5 inhibitorok alkalmazása perifériás érbetegségek, perifériás neuropátiák és autonóm neuropátiák kezelésére szolgáló gyógyszerkészítmények elżállítására
John et al. Control strategies for the dynamics of catheter-associated urinary tract infection
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
MX2024007796A (es) Métodos y composiciones para mejorar el rendimiento en el ejercicio.
Venner et al. MCRN¯ 003/MYX· 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies
RU2021132757A (ru) Фармацевтическая композиция, содержащая дигидрокверцетин, трутневый расплод, витамин Д3, применение для профилактики и лечения сердечно-сосудистых патологий
ZA202211118B (en) Treatment of viral infection by apheresis
Starr First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma.
Safi et al. Update: Brain protection via cerebral retrograde perfusion during aortic arch aneurysm repair